Search Clinical Trials
By Condition
By Location (USA)
By Location (Other)
By Sponsor
Resources
Privacy Policy
About Us
Disclaimer
A study of Rituxan in the treatment of polyneuropathies associated with serum IgM autoantibodies Clinical Trials Data presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, calls or treatment using a genuine doctor. We are not docs. Always consult your dr. on A study of Rituxan in the treatment of polyneuropathies associated with serum IgM autoantibodies conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. A study of Rituxan in the treatment of polyneuropathies associated with serum IgM autoantibodies Clinical research trials and A study of Rituxan in the treatment of polyneuropathies associated with serum IgM autoantibodies healthcare trials occur in a lot of of places throughout the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the potency of new drugs. The intent of the studies / undertakings is to figure out certain human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector corporations to locate remedies for all kinds of circumstances, including A study of Rituxan in the treatment of polyneuropathies associated with serum IgM autoantibodies. A study of Rituxan in the treatment of polyneuropathies associated with serum IgM autoantibodies Clinical Trials and other clinical trials allow volunteers to obtain health treatment alternatives before they are available to the masses. Many times the participants undergo treatment for free, and sometimes they are paid for their time. Occasionally there is a cost for a A study of Rituxan in the treatment of polyneuropathies associated with serum IgM autoantibodies clinical trial. Participants typically obtain the most effective healthcare available for their A study of Rituxan in the treatment of polyneuropathies associated with serum IgM autoantibodies condition. Dangers are a reality, nonetheless, and can include extra or frequent mD trips, medical hazards (potentially life-endangering), and/or the treatment being uneffective. Trials are federally regulated with rigid guidelines to protect clinical trials patients.

Home > "A" Clinical Trials Conditions > A study of Rituxan in the treatment of polyneuropathies associated with serum IgM autoantibodies

A study of Rituxan in the treatment of polyneuropathies associated with serum IgM autoantibodies



A study of Rituxan in the treatment of polyneuropathies associated with serum IgM autoantibodies

For Condition: Peripheral Neuropathy
Status: No longer recruiting
Sponsor(s): National Center for Research Resources (NCRR) , Genentech
Synopsis: Peripheral neuropathies cause weakness and sensory loss that can produce severe disability. Some neuropathies are immune-mediated and associated with antibodies. It has been postulated that Rituxan treatment may reduce the level of antibody production limiting the loss of muscle strength and hence improve activities of daily living. The purpose of this open-label study (all participants get Rituxan and not placebo) is to determine the safety and effectiveness of Rituxan in the treatment of polyneuropathies associated with serum IgM autoantibodies in those who have already been treated with one course of Rituxan. Subjects will be treated on the in-patient Clinical Research Center with Rituxan for two treatments one week a part and then individual treatments every 10 weeks for one year. The effectiveness of Rituxan will be followed by looking for increases in muscle strength and decreases in the serum IgM autoantibodies.
Details:
Eligibility:
Study Type:
  Interventional, Treatment, Open Label
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Diagnosis of characteristic peripheral neuropathy by appropriate history, physical examination, nerve conduction findings and serum autoantibodies. - Serum anti-GM1 on anti-MAG antibodies present at high titers in serum, continued by testing in the neuromuscular clinical laboratory at Washington University.
Total Enrollment: 

Location and Contact Information:


Additional Information:
Study ID Numbers:
  NCRR-M01RR00036-0690;  M01RR00036
Study Start Date: 
Record last reviewed: July 2000
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00006072

Other Peripheral Neuropathy Studies:
1. Painful HIV Neuropathy and Alpha-Lipoic Acid

2. Achilles Tendon Lengthening in Patients with Diabetes to Prevent Foot Ulcers

3. A study of Rituxan in the treatment of polyneuropathies associated with serum IgM autoantibodies

Related Studies:

Other Peripheral Neuropathy Clinical Trials
Other Clinical Trials
Other Clinical Trials

A study of Rituxan in the treatment of polyneuropathies associated with serum IgM autoantibodies

Modify your Search

  Other Peripheral Neuropathy Clinical Trials
  Other Clinical Trials
  Other Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103